海外の治験の状況「1」での検索結果
1495件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
- First Line Non-Small Cell Lung Cancer
- Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2015-10-13
Not recruiting
- Phase II, 2nd Line Melanoma - RAND Monotherapy
- Melanoma
- Austria, Brazil, Canada, Denmark, France, Germany, Italy, United States
- 2008-01-30
Not recruiting
- Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans
- Healthy
- Austria
- 2009-06-01
Authorised
- First-line treatment for different subgroups of lymphomas
- Indolent Non-Hodgkin Lymphomas, in particular follicular lymphomas, as well as marginal zone lymphomas, immunocytomas (Waldenström’s macroglobulinaemia) and mantle cell lymphomas;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany
- 2008-11-20
Not recruiting
- A Study in Second Line Metastatic Colorectal Cancer
- Colorectal Cancer;Colorectal Cancer;Colorectal Cancer;Colorectal Cancer
- Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Netherlands, Portugal, Puerto Rico, Romania, Slovenia, Spain, Sweden, Taiwan, United States
- 2010-08-04
Not Recruiting
- SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS
- Moderate to severe spasticity due to MS (multiple sclerosis). MedDRA version: 19.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria, Czech Republic
- 2015-12-22
Authorised
- Pembrolizumab as First Line Treatment in Subjects with Recurrent/Metastatic HNSCC.
- Recurrent/metastatic head and neck squamous cell carcinoma. MedDRA version: 20.0 Level: PT Classification code 10071540 Term: Head and neck cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2014-12-22
Not recruiting
- Dose-Finding Trial With Sugammadex at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Subjects of ASA Class 1-3 (19.4.206)(P05944)
- Anesthesia, General;Anesthesia, General;Anesthesia, General;Anesthesia, General
- Austria, Denmark, Germany
- 2007-09-25
Not recruiting
- AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
- Advanced Renal Cell Carcinoma
- Austria, Belgium, France, Poland, United States
- 2007-04-26
Not recruiting
- Clinical study to assess the efficacy and safety of a new antiretroviral drug (MPC-4326) in patients with Human immunodeficiency virus-1 (HIV-1) infection over a period of 14 days to 72 weeks.
- HIV-1
- Australia, Belgium, New Zealand, Poland
- 2008-05-21